The essential role of the intestinal microbiota in facilitating acute inflammatory responses.
The restoration of blood flow, i.e., reperfusion, is the treatment of choice to save viable tissue following acute ischemia of a vascular territory. Nevertheless, reperfusion can be accompanied by significant inflammatory events that limit the beneficial effects of blood flow restoration. To evaluate the potential role of the intestinal microbiota in facilitating the development of tissue injury and systemic inflammation, germ-free and conventional mice were compared in their ability to respond to ischemia and reperfusion injury. In conventional mice, there was marked local (intestine) and remote (lung) edema formation, neutrophil influx, hemorrhage, and production of TNF-alpha, KC, MIP-2, and MCP-1. Moreover, there was an increase in the concentration of serum TNF-alpha and 100% lethality. In germ-free mice, there was no local, remote, or systemic inflammatory response or lethality after intestinal ischemia and reperfusion and, in contrast to conventional mice, germ-free animals produced greater amounts of IL-10. Similar results were obtained after administration of LPS, i.e., little production of TNF-alpha or lethality and production of IL-10 after LPS in germ-free mice. Blockade of IL-10 with Abs induced marked inflammation and lethality in germ-free mice after ischemia and reperfusion or LPS administration, demonstrating that the ability of these mice to produce IL-10 was largely responsible for their "no inflammation" phenotype. This was consistent with the prevention of reperfusion-associated injury by the exogenous administration of IL-10 to conventional mice. Thus, the lack of intestinal microbiota is accompanied by a state of active IL-10-mediated inflammatory hyporesponsiveness.
Souza
Danielle G
DG
Departament of Bioquímica e Imunologia e, Universidade Federal de Minas Gerais (UFMG), Pampulha, Belo Horizonte, Brazil.
Vieira
Angélica T
AT
Soares
Adriana C
AC
Pinho
Vanessa
V
Nicoli
Jacques R
JR
Vieira
Leda Q
LQ
Teixeira
Mauro M
MM
D000208:Acute Disease; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D018988:Bacterial Translocation / Q000276:immunology; D005856:Germ-Free Life; D007106:Immune Sera / Q000008:administration & dosage; D007108:Immune Tolerance; D007249:Inflammation / Q000276:immunology* / Q000382:microbiology* / Q000401:mortality / Q000473:pathology; D007274:Injections, Intraperitoneal; D016753:Interleukin-10 / Q000008:administration & dosage / Q000096:biosynthesis / Q000276:immunology; D007413:Intestinal Mucosa / Q000098:blood supply / Q000276:immunology / Q000382:microbiology* / Q000473:pathology*; D008070:Lipopolysaccharides / Q000008:administration & dosage / Q000633:toxicity; D017737:Macrophages, Peritoneal / Q000276:immunology / Q000378:metabolism; D051379:Mice; D015427:Reperfusion Injury / Q000276:immunology / Q000382:microbiology / Q000401:mortality / Q000517:prevention & control; D013997:Time Factors
D000900:Anti-Bacterial Agents; D007106:Immune Sera; D008070:Lipopolysaccharides; D016753:Interleukin-10